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ABSTRACT
Analysis of tissues retrieved from the bone–pannus
interface from patients with rheumatoid arthritis (RA) and
studies in animal models of inflammatory arthritis provide
strong evidence that osteoclasts, the cells that are
essential for physiological bone resorption, are responsible
for articular bone destruction in RA. However, current
treatments that specifically target osteoclast-mediated
bone resorption in RA have not been successful in
preventing bone erosions, and new therapeutic strategies
are needed. It has been noted that, although osteoclast
precursors are present within the bone microenvironment
at sites of pathological bone resorption, cells expressing
the full morphological and functional properties of mature
osteoclasts are restricted to the immediate bone surface
and adjacent calcified cartilage. These findings provide
evidence that, in addition to requirements for specific
cytokines, interaction of osteoclast precursors with these
mineralised matrices results in activation of specific signal
pathways and the induction of unique gene products that
are essential for terminal osteoclast differentiation and
activation. These studies are designed to define the gene
products and signalling pathways regulated by bone and
calcified cartilage, to identify new molecular targets and
novel therapeutic approaches for preventing osteoclast-
mediated joint destruction in RA and related forms of
pathological bone loss.
The development of in vitro cell models for
studying osteoclast differentiation and the analysis
of human and murine disorders associated with
defective osteoclast differentiation and activation
have established that osteoclasts are derived from a
haematopoietic precusor of myeloid origin.1 2 Both
murine and human bone marrow culture systems
have been particularly informative in dissecting the
regulatory mechanisms and commitment points in
the cytodifferentiation pathway of this bone-
resorbing cell. The initial event associated with
osteoclast commitment requires interaction with
the haematopoietic growth factor, macrophage
colony-stimulating factor-1 (M-CSF), which acts
via its receptor CSF-1R. At this early stage, the
myeloid lineage cell retains its pluri-potential
ability to differentiate down the macrophage or
osteoclast pathway. Thus, the tissue macrophage
and osteoclast share a common haematopoietic
origin with other colony-forming unit-macrophage
lineage cells, including macrophages that populate
the lung (alveolar macrophages), liver (Kupfer
cells), synovium (synovial macrophages) and other
organs. Osteoclasts also share a common lineage
with dendritic cells and macrophage polykaryons
(foreign body giant cells) that are involved in
immunoregulation and a variety of granulomatous
disorders.
After interaction with M-CSF, the further
commitment, differentiation and activation of
osteoclasts is mediated by a complex network of
regulatory factors, including systemic hormones,
locally produced cytokines and cell–cell and cell–
matrix interactions that are required for transition
of the osteoclast precursor into a multinucleated
and fully activated cell capable of resorbing the
mineral and organic matrix of bone.1 3–5 A major
breakthrough in the understanding of the regula-
tion osteoclast of differentiation came with the
identification of RANKL (receptor activator of NF-
kB ligand).6–8 This cytokine is a product of stromal
cells that are of osteoblast lineage and it is both
necessary and sufficient for osteoclast formation.
RANKL is a member of the tumour necrosis factor
a family and it mediates its effects via a specific
receptor, RANK (receptor activator of NF-kB).
Deletion of either RANKL or its receptor leads to
a severe form of osteopetrosis,9 10 providing defini-
tive evidence for the essential role of this ligand-
receptor system in controlling osteoclast differen-
tiation and bone resorption.
Although the osteoclast precursor may be
derived from both the bone marrow and cells
present within the circulation, the assembly of the
terminally differentiated osteoclast probably
occurs on the bone surface. There is evidence that
the initial event associated with osteoclast pre-
cursor attachment may involve interaction with
cells that line the trabecular bone surface via
adhesion molecules such as intercellular adhesion
molecule-1 or vascular cell adhesion molecule-1.11–13
Attachment of the osteoclast precursor then leads
to retraction of the lining cells and exposure of the
bone surface.12 These events appear to involve
matrix metalloproteinase (MMP) activity that
cleaves type I collagen on the bone surface and
reveals cryptic binding sites for integrins that are
necessary for optimal preosteoclast attachment.14–16
Evidence supporting a role for MMPs is provided
by the studies of Holliday et who used an in vitro
model of osteoclast differentiation to show that
collagenase inhibition decreases preosteoclast
attachment and inhibits osteoclast-mediated bone
resorption.17 Further support implicating protei-
nase activity in osteoclast-mediated bone resorp-
tion is provided by the studies of Zhao et al
who showed that bone resorption induced
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by parathyroid hormone was markedly impaired in MMP13-
resistant mutant mice.18
The subsequent steps of osteoclast differentiation that follow
attachment are associated with the temporal induction of a
genetic programme that is associated with sequential acquisi-
tion of the functional machinery that is necessary for multi-
nucleation of the precursor and reorganisation of the
cytoskeletal that results in cell surface membrane polarisation
and specialisation. The attachment of the precursor involves
interaction with cell surface receptors, including the vitronectin
receptor avb3, the collagen/laminin receptor a2b1 and the
vitronectin/fibronectin receptor avb1.
19 During osteoclast differ-
entiation, the b5 and b3 integrins are reciprocally regulated,
with downregulation of b5 and upregulation of the b3
integrin.20 In our recent studies we have found that b3 integrin
is expressed relatively late in the sequence of osteoclast
differentiation, after the induction of osteoclast-associated
genes such as tartrate-resistant acid phosphatase (TRAP) and
cathepsin K. This would suggest that the initial attachement of
the osteoclast precursor does not involve the b3 integrin, but is
mediated via alternate attachment receptors. In support of this
speculation, the b3 integrin is not essential for preosteoclast
attachment, since, as we previously reported, the b3 knockout
mouse expresses normal or even slightly increased numbers of
osteoclasts on the bone surfaces.21 The reduced ability of the b3
knockout mice to resorb bone implies, however, that signalling
through this protein is essential for optimal functional
osteoclast resorbing activity since the mice develop a mild form
of osteopetrosis related to defective bone resorbing activity.
In preliminary studies, we have analysed the genetic profile of
osteoclast precursors derived from the b3 knockout mouse after
differentiation on bone surfaces and found that although the
prototypical osteoclast-associated genes such as TRAP and
cathepsin K are induced during osteoclast differentiation, the
pattern of gene expression in the terminally differentiated
osteoclast derived from the b3 knockout mouse differs markedly
from wild-type osteoclast precursors. These observations
provide evidence that interaction of osteoclast precursors with
the bone surface can markedly affect the genetic programme
and phenotype of osteoclasts and that the b3 integrin is among
the cell surface recognition molecules that mediate a component
of the bone-regulated genetic programme.
Further evidence supporting a role of the bone matrix in
regulating osteoclast differentiation and activation is provided
by analysis of the tissues from sites of bone resorption in
patients with rheumatoid arthritis (RA) and juvenile inflam-
matory arthritis.22 23 We found that, although there were cells
within the inflamed synovium that expressed TRAP and low
levels of cathepsin K protein or mRNA, cells expressing the full
repertoire of osteoclast-associated phenotypic markers were
localised exclusively to the immediate bone surfaces. Further
evidence supporting the importance of cell–substrate interac-
tions in modulating cell phenotype is provided by comparison
of the phenotype of mono- and multinucleated cells associated
with wear particles and bone surfaces from patients under-
going revision surgery for peri-implant osteolysis related to
prosthetic implant wear debris after total joint replacement.4
Cells associated with wear particles were strongly CD68
positive, consistent with their classification as macrophages
or macrophage polykaryons. We observed that although many
of these cells expressed low levels of cathepsin K and TRAP, the
levels of expression were markedly reduced compared with
mono- and multinucleated cells in resorption lacunae on the
bone surfaces. In contrast, we noted that cells expressing two
other osteoclast-associated proteins—namely, the calcitonin
receptor and b3 integrin, were restricted to the bone surface.
These findings provided further evidence implicating cell–
substrate interactions in regulating terminal osteoclast differ-
entiation and activation.
Based on the differential expression of the calcitonin receptor
and b3 integrin in osteoclasts on or off the bone surface, we
speculated that these these two proteins were representative of
a family of genes that were components of a larger genetic
programme that was dependent upon interaction of the
osteoclast with the bone substrate. To further identify the
potentially novel osteoclast genes and signal pathways regu-
lated by bone–substrate interactions we developed a model for
induction of osteoclast differentiation on discs of devitalised
calvarial mouse bone. This model provides a unique experi-
mental approach for analysis of the effects of mineralised bone
surfaces on osteoclast phenotype and for identification of
specific gene products and signal pathways involved in bone
matrix-dependent terminal osteoclast differentiation and acti-
vation.
Discs of bone were prepared from mouse calvaria (4 mm)
using a leather punch. The samples were devitalised by repeated
freeze thawing followed by treatment with collagenase, which
markedly enhanced the attachment of osteoclast precursors to
the bone surface. Mouse bone marrow macrophages were then
seeded onto the bone discs and cells cultured with M-CSF
(20 ng/ml) and RANKL (20 ng/ml) for 5–7 days. The incuba-
tions were conducted on discs that had been placed in wells in
24 tissue culture trays. The discs occupied only a portion of the
surface of the well, providing a system in which osteoclasts
formed on either plastic or bone within the same well could be
compared.
After osteoclast induction, cells adherent to the tissue culture
plastic or on the bone were fixed with 4% paraformaldehyde for
histological examination. RNA was isolated from either the
plastic- or bone-adherent populations in replicate cultures to
enable comparison of the transcriptional profiles in osteoclast
precursors differentiated on bone or tissue culture plastic. RNA
prepared from the cultured cells was reverse transcribed and
cDNA analysed by oligonucleotide array expression profiling on
Affymetrix Mouse Genome 430 2.0 GeneChips. After micro-
array normalisation and gene comparison, hierarchical cluster-
ing was performed on the subset of genes showing the greatest
amount of variation using the dChip 1.3 program.
In our preliminary analyses we identified clusters of genes
that were specifically up- or downregulated by adhesion to the
bone or plastic. We chose to focus initial attention on
characterisation of the expression pattern and functional role
of genes with the largest fold induction and for which antibody
and other reagents are available. This approach ensured that we
could test bone matrix-dependent expression at the protein level
by western blot and in vivo by immunohistochemistry.
Importantly, the availability of suitable reagents also permitted
validation of the genes as suitable targets for inhibiting
osteoclast-mediated bone resorption in animal models. The
authenticity of the gene profiles as markers of osteoclast
differentiation and activation were provisionally validated by
examination of tissues from patients with pathological osteo-
clast-mediated bone resorption associated with RA or peri-
implant osteolysis.
We are in the process of more rigorously characterising the
bone-regulated genes with the goal of identifying new molecular
targets for inhibiting osteoclast-mediated bone loss in RA and
related disorders of pathological bone loss.
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CONCLUSION
Our findings provide evidence that, in addition to requirements
for specific cytokines, interaction of osteoclast precursors with
these mineralised matrices results in activation of specific signal
pathways and the induction of unique gene products that are
essential for terminal osteoclast differentiation and activation.
Our preliminary studies have defined specific gene products and
signalling pathways regulated by bone and calcified cartilage.
These studies will permit the identification of new molecular
targets and novel therapeutic approaches for preventing
osteoclast-mediated joint destruction in RA and related forms
of pathological bone loss.
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